Innovative lipid-lowering therapy: experience of inclisiran use in the Republic of Belarus

Abstract

The article reflects modern aspects of lipid-lowering therapy, based on the as­sessment of cardiovascular risk, and the possibilities of triple therapy, including statins, ezetimibe, and inclisiran.We present our own data on the use of the drug inclisiran in patients with lipid metabolism disorders in the framework of secondary and primary cardiovascular prevention. Low-density lipoprotein levels at different times after the injection is described. The potential of innovative lipid-lowering therapy in liver transplant recipients in the long-term postoperative period are discussed.The addition of inclisiran to statin and ezetimibe therapy is safe and leads to a decrease in low-density lipoprotein levels by more than 50% of baseline values in the general population.